DocGo 2026 guidance, starts strategic review
DocGo raises 2026 guidance amid ongoing losses and cash constraints, launches strategic alternatives review
- Q4 non-GAAP EPS -$1.37 (-4467% YoY) missed estimates, while revenue $74.9M (-38% YoY) beat expectations.
- Q4 and full-year 2025 results show $196.4 million net loss driven by asset impairments.
- Company discloses formal review of strategic alternatives in SEC filing today.
- Investor Takeaway – Core businesses grew double-digit ex-migrant, but company remains loss-making and cash-constrained.
- Biggest Positive – Raised 2026 revenue and EBITDA guidance on stronger transport demand and SteadyMD momentum.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.